miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 4, 2026

South Korea report: domestic sales fall 15% in February

View original at finance.yahoo.com
South Korea report: domestic sales fall 15% in February Domestic sales by South Korea’s five main automakers combined fell by 15% to 95,638 units in February 2026 from 112,258 units a year earlier, according to preliminary wholesale data released individually by the main local manufacturers…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The timing of this year's Lunar New Year holidays caused the sharp drop in domestic sales

    80% confidence

  • Kia is targeting an almost 7% increase in global sales to 3,350,000 units in 2026, including 565,000 domestic sales and 2,775,000 overseas, along with 10,000 global SPV sales

    80% confidence

  • This includes 915,000 deliveries in the US, 594,000 units in Europe, and 302,000 units in India

    80% confidence

  • The company plans to introduce at least eight new models by 2030

    80% confidence

  • The company is looking for continued product mix improvement and new model launches this year to help offset rising competition, economic uncertainty and US import tariffs

    80% confidence

  • GM Korea has pledged to invest US$ 300 million to upgrade its local manufacturing operations for the production of next-generation models

    80% confidence

  • Sales in North America are forecast to increase slightly to 1,231,000 units, while sales in Europe are expected to be flat at 601,000 units; India 592,000 units (+3%), South Korea 700,000 units (-2%), and South America 328,000 units (+0.1%)

    80% confidence

  • KGM plans to release new and upgraded models with improved performance in 2026 to help strengthen its domestic and overseas sales, with a focus on expanding its zero-emissions vehicle range

    80% confidence

  • Hyundai is targeting a slight increase in global sales to 4.158 million units in 2026, including its Genesis luxury brand, with domestic sales expected to reach 700,000 units and 3.46 million units overseas

    80% confidence

  • The company has set a target of producing 500,000 vehicles in 2026, up from 462,310 units in 2025, mainly to meet growing overseas demand, particularly in the US

    80% confidence

  • The company plans to continue to expand its hybrid lineup to include the new Telluride and Seltos SUV models in the US, the new EV2 BEV models in Europe, and the all-new Seltos in India

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
South Korea report: domestic sales fall 15% in February — Source | Via News | es.VIA.NEWS